Folkerts K - Search Results

1

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Monreal M, et al. Among authors: folkerts k. Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22. Thromb Haemost. 2013. PMID: 23965805 Clinical Trial.

2

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.

McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J. McDonald H, et al. Among authors: folkerts k. J Med Econ. 2012;15(5):817-28. doi: 10.3111/13696998.2012.684116. Epub 2012 Apr 24. J Med Econ. 2012. PMID: 22494267 Free article.

3

Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies.

Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Khoury H, et al. Among authors: folkerts k. Thromb Haemost. 2011 Oct;106(4):600-8. doi: 10.1160/TH11-03-0168. Epub 2011 Aug 11. Thromb Haemost. 2011. PMID: 21833448 Review.

4

Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.

Folkerts K, Broughton J, Sheikh U, Mckaig S. Folkerts K, et al. J Med Econ. 2019 Nov;22(11):1179-1191. doi: 10.1080/13696998.2019.1658589. Epub 2019 Sep 19. J Med Econ. 2019. PMID: 31433687 Free article.

5

Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.

Martinez C, Katholing A, Folkerts K, Cohen AT. Martinez C, et al. Among authors: folkerts k. J Thromb Haemost. 2016 Jul;14(7):1374-83. doi: 10.1111/jth.13337. Epub 2016 Jun 7. J Thromb Haemost. 2016. PMID: 27079164 Free article.

6

Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study.

Cohen AT, Maraveyas A, Beyer-Westendorf J, Lee AYY, Folkerts K, Abdelgawwad K, De Sanctis Y, Fatoba S, Bamber L, Bach M, Mantovani LG; COSIMO Investigators. Cohen AT, et al. Among authors: folkerts k. Thromb Res. 2021 Oct;206:1-4. doi: 10.1016/j.thromres.2021.06.021. Epub 2021 Jul 2. Thromb Res. 2021. PMID: 34332213 Free article. No abstract available.

7

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis.

Cano S, Mantovani L, Folkerts K, Gebel M, Sahin K, Zell E, Monje D, Schneider J, Eickels MV, Haas S, Kreutz R, Ageno W, Turpie AGG. Cano S, et al. Among authors: folkerts k. TH Open. 2018 Apr 11;2(2):e139-e146. doi: 10.1055/s-0038-1641679. eCollection 2018 Apr. TH Open. 2018. PMID: 31249937 Free PMC article.

8

The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease.

Khoury H, Lavoie L, Welner S, Folkerts K. Khoury H, et al. Among authors: folkerts k. Cardiovasc Ther. 2016 Apr;34(2):115-24. doi: 10.1111/1755-5922.12169. Cardiovasc Ther. 2016. PMID: 26670723 Free article. Review.

9

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.

Mantovani LG, Haas S, Kreutz R, Folkerts K, Gebel M, Monje D, Schneider J, van Eickels M, Sahin K, Zell E, Ageno W, Turpie AGG. Mantovani LG, et al. Among authors: folkerts k. Eur J Intern Med. 2019 Mar;61:29-33. doi: 10.1016/j.ejim.2018.10.002. Epub 2018 Oct 19. Eur J Intern Med. 2019. PMID: 30342973 Free article.

10

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.

Briere JB, Bowrin K, Coleman C, Fauchier L, Levy P, Folkerts K, Toumi M, Taieb V, Millier A, Wu O. Briere JB, et al. Among authors: folkerts k. Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):27-36. doi: 10.1080/14737167.2018.1518134. Epub 2018 Sep 19. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30169975

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page